The next generation biopharmaceuticals
Affibody is a Swedish biotech company focused on developing next generation biopharmaceuticals based on its unique proprietary technology platforms: Affibody® molecules and Albumod™.
Affibodys latest Press releases
Solna, Sweden, September 6, 2017. Affibody AB (“Affibody”), a clinical stage next generation biopharmaceutical company developing a portfolio of innovative drug projects, today announced...[read more]
Affibody´s strengths and advantages
Our mission is to improve the lives of patients with serious diseases by being a research-driven company with a long term commitment to development of proteinbased drugs.
Affibody is developing innovative protein therapeutics in areas where our unique technology platforms gives us the advantage.
Highly qualified resources
Operations are conducted by highly qualified resources in research and development and is based on the company's proprietary technology platforms.